Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18516
Country/Region: Kenya
Year: 2018
Main Partner: Mkomani Clinic Society
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $4,162,707 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $431,519
Care: TB/HIV (HVTB) $205,240
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $72,724
Testing: HIV Testing and Counseling (HVCT) $246,615
Sexual Prevention: Other Sexual Prevention (HVOP) $654,511
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $202,840
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $112,926
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $2,006,360
Treatment: Pediatric Treatment (PDTX) $229,972
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_SELF 2019 288
HTS_SELF 15-19, Female, Directly-Assisted 2019 16
HTS_SELF 15-19, Female, Unassisted 2019 16
HTS_SELF 15-19, Male, Directly-Assisted 2019 5
HTS_SELF 15-19, Male, Unassisted 2019 5
HTS_SELF 20-24, Female, Directly-Assisted 2019 15
HTS_SELF 20-24, Female, Unassisted 2019 16
HTS_SELF 20-24, Male, Directly-Assisted 2019 5
HTS_SELF 20-24, Male, Unassisted 2019 5
HTS_SELF 25-29, Female, Directly-Assisted 2019 16
HTS_SELF 25-29, Female, Unassisted 2019 16
HTS_SELF 25-29, Male, Directly-Assisted 2019 5
HTS_SELF 25-29, Male, Unassisted 2019 5
HTS_SELF 30-34, Female, Directly-Assisted 2019 16
HTS_SELF 30-34, Female, Unassisted 2019 16
HTS_SELF 30-34, Male, Directly-Assisted 2019 5
HTS_SELF 30-34, Male, Unassisted 2019 5
HTS_SELF 35-39, Female, Directly-Assisted 2019 16
HTS_SELF 35-39, Female, Unassisted 2019 16
HTS_SELF 35-39, Male, Directly-Assisted 2019 5
HTS_SELF 35-39, Male, Unassisted 2019 5
HTS_SELF 40-49, Female, Directly-Assisted 2019 16
HTS_SELF 40-49, Female, Unassisted 2019 16
HTS_SELF 40-49, Male, Directly-Assisted 2019 5
HTS_SELF 40-49, Male, Unassisted 2019 5
HTS_SELF 50+, Female, Directly-Assisted 2019 16
HTS_SELF 50+, Female, Unassisted 2019 16
HTS_SELF 50+, Male, Directly-Assisted 2019 5
HTS_SELF 50+, Male, Unassisted 2019 5
HTS_SELF Directly-Assisted 2019 144
HTS_SELF FSW, Directly-Assisted 2019 193
HTS_SELF MSM, Directly-Assisted 2019 43
HTS_SELF PWID, Directly-Assisted 2019 17
HTS_SELF Unassisted 2019 144
HTS_SELF Unassisted - Other 2019 15
HTS_SELF Unassisted - Self 2019 72
HTS_SELF Unassisted - Sex Partner 2019 58
HTS_TST 15-19, Female, Negative 2019 18
HTS_TST 15-19, Male, Negative 2019 50
HTS_TST 20-24, Female, Negative 2019 64
HTS_TST 20-24, Male, Negative 2019 159
HTS_TST 25-29, Female, Negative 2019 1,813
HTS_TST 25-29, Female, Negative 2019 57
HTS_TST 25-29, Female, Negative 2019 28
HTS_TST 25-29, Female, Negative 2019 408
HTS_TST 25-29, Female, Negative 2019 12
HTS_TST 25-29, Female, Negative 2019 89
HTS_TST 25-29, Female, Negative 2019 10
HTS_TST 25-29, Female, Negative 2019 714
HTS_TST 25-29, Male, Negative 2019 531
HTS_TST 25-29, Male, Negative 2019 8
HTS_TST 25-29, Male, Negative 2019 37
HTS_TST 25-29, Male, Negative 2019 61
HTS_TST 25-29, Male, Negative 2019 4
HTS_TST 25-29, Male, Negative 2019 18
HTS_TST 25-29, Male, Negative 2019 1
HTS_TST 30-34, Female, Negative 2019 777
HTS_TST 30-34, Female, Negative 2019 1,813
HTS_TST 30-34, Female, Negative 2019 65
HTS_TST 30-34, Female, Negative 2019 26
HTS_TST 30-34, Female, Negative 2019 468
HTS_TST 30-34, Female, Negative 2019 14
HTS_TST 30-34, Female, Negative 2019 102
HTS_TST 30-34, Female, Negative 2019 12
HTS_TST 30-34, Male, Negative 2019 656
HTS_TST 30-34, Male, Negative 2019 10
HTS_TST 30-34, Male, Negative 2019 40
HTS_TST 30-34, Male, Negative 2019 73
HTS_TST 30-34, Male, Negative 2019 4
HTS_TST 30-34, Male, Negative 2019 22
HTS_TST 30-34, Male, Negative 2019 2
HTS_TST 35-39, Female, Negative 2019 304
HTS_TST 35-39, Female, Negative 2019 1,813
HTS_TST 35-39, Female, Negative 2019 16
HTS_TST 35-39, Female, Negative 2019 32
HTS_TST 35-39, Female, Negative 2019 117
HTS_TST 35-39, Female, Negative 2019 4
HTS_TST 35-39, Female, Negative 2019 25
HTS_TST 35-39, Female, Negative 2019 3
HTS_TST 35-39, Male, Negative 2019 215
HTS_TST 35-39, Male, Negative 2019 10
HTS_TST 35-39, Male, Negative 2019 56
HTS_TST 35-39, Male, Negative 2019 73
HTS_TST 35-39, Male, Negative 2019 4
HTS_TST 35-39, Male, Negative 2019 22
HTS_TST 35-39, Male, Negative 2019 2
HTS_TST 40-49, Female, Negative 2019 304
HTS_TST 40-49, Female, Negative 2019 1,813
HTS_TST 40-49, Female, Negative 2019 16
HTS_TST 40-49, Female, Negative 2019 25
HTS_TST 40-49, Female, Negative 2019 117
HTS_TST 40-49, Female, Negative 2019 4
HTS_TST 40-49, Female, Negative 2019 25
HTS_TST 40-49, Female, Negative 2019 3
HTS_TST 40-49, Male, Negative 2019 73
HTS_TST 40-49, Male, Negative 2019 4
HTS_TST 40-49, Male, Negative 2019 51
HTS_TST 40-49, Male, Negative 2019 24
HTS_TST 40-49, Male, Negative 2019 1
HTS_TST 40-49, Male, Negative 2019 7
HTS_TST 40-49, Male, Negative 2019 1
HTS_TST 50+, Female, Negative 2019 8
HTS_TST 50+, Male, Negative 2019 1
HTS_TST By Key Population: FSW, Negative 2019 109
HTS_TST By Key Population: MSM, Negative 2019 16
HTS_TST By Key Population: PWID, Negative 2019 1
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 33,495
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2019 3
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2019 9
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2019 12
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2019 30
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 8
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 1,467
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 3,979
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 23
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 69
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 304
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 145
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 102
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 10
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 24
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 34
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 32
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 2
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 5
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 27
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 12
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 9
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 26
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 64
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 90
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 204
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 13
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 1,427
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 619
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 491
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 328
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 864
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 1,137
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 2,756
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 151
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 35
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 806
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 16
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 20
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 18
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 30
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 36
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 30
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 36
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 23
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 42
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 29
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 148
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 67
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 51
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 135
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 360
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 464
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 1,155
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 59
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 13
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 248
HTS_TST_POS 20-24, Male, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 62
HTS_TST_POS 25-29, Female, Positive 2019 8
HTS_TST_POS 25-29, Female, Positive 2019 51
HTS_TST_POS 25-29, Female, Positive 2019 60
HTS_TST_POS 25-29, Female, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 26
HTS_TST_POS 25-29, Male, Positive 2019 20
HTS_TST_POS 25-29, Male, Positive 2019 10
HTS_TST_POS 25-29, Male, Positive 2019 7
HTS_TST_POS 25-29, Male, Positive 2019 8
HTS_TST_POS 30-34, Female, Positive 2019 28
HTS_TST_POS 30-34, Female, Positive 2019 15
HTS_TST_POS 30-34, Female, Positive 2019 6
HTS_TST_POS 30-34, Female, Positive 2019 57
HTS_TST_POS 30-34, Female, Positive 2019 68
HTS_TST_POS 30-34, Female, Positive 2019 1
HTS_TST_POS 30-34, Female, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 23
HTS_TST_POS 30-34, Male, Positive 2019 10
HTS_TST_POS 30-34, Male, Positive 2019 10
HTS_TST_POS 30-34, Male, Positive 2019 10
HTS_TST_POS 35-39, Female, Positive 2019 11
HTS_TST_POS 35-39, Female, Positive 2019 13
HTS_TST_POS 35-39, Female, Positive 2019 9
HTS_TST_POS 35-39, Female, Positive 2019 14
HTS_TST_POS 35-39, Female, Positive 2019 17
HTS_TST_POS 35-39, Male, Positive 2019 8
HTS_TST_POS 35-39, Male, Positive 2019 15
HTS_TST_POS 35-39, Male, Positive 2019 9
HTS_TST_POS 35-39, Male, Positive 2019 10
HTS_TST_POS 40-49, Female, Positive 2019 11
HTS_TST_POS 40-49, Female, Positive 2019 8
HTS_TST_POS 40-49, Female, Positive 2019 6
HTS_TST_POS 40-49, Female, Positive 2019 14
HTS_TST_POS 40-49, Female, Positive 2019 17
HTS_TST_POS 40-49, Male, Positive 2019 3
HTS_TST_POS 40-49, Male, Positive 2019 14
HTS_TST_POS 40-49, Male, Positive 2019 3
HTS_TST_POS 40-49, Male, Positive 2019 3
HTS_TST_POS By Key Population: FSW, Positive 2019 2
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 41
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 21
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 57
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 66
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 188
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 62
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 27
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 21
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 33
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 43
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 103
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) VCT: <1, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 38
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 44
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 58
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 142
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 1
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 20
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 417
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 437
OVC_SERV Age/Sex: <1 2019 25
OVC_SERV Age/Sex: 1-9 2019 1,677
OVC_SERV Age/Sex: 10-14 Female 2019 850
OVC_SERV Age/Sex: 10-14 Male 2019 841
OVC_SERV Age/Sex: 15-17 Female 2019 450
OVC_SERV Age/Sex: 15-17 Male 2019 426
OVC_SERV By: Age/sex: 18-24 Female 2019 208
OVC_SERV By: Age/sex: 25+ Female 2019 5
OVC_SERV By: Age/sex: Male 18-24 2019 233
OVC_SERV By: Age/sex: Male 25+ 2019 5
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 4,720
OVC_SERV Program Completion: Active 2019 4,717
OVC_SERV Program Completion: Graduation 3 Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner. 4,309 Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 4,720
OVC_SERV Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24 2019 821
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14 2019 226
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17 2019 1,371
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24 2019 1,642
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14 2019 1,507
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17 2019 2,742
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24 2019 3,284
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14 2019 904
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17 2019 274
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14 2019 409
OVC_SERV Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17 2019 274
OVC_SERV Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24 2019 328
OVC_SERV Sum of Age/Sex disaggregates 2019 2,567
PMTCT_ART Already on ART at beginning of current pregnancy 2019 759
PMTCT_ART New on ART 2019 137
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 896
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 2,635
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 264
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 264
PMTCT_EID Sum of Infant Age disaggregates 2019 264
PMTCT_STAT 25-29, Female 2019 435
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 130
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 224
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 21
PMTCT_STAT 30-34, Female 2019 249
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 130
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 224
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 21
PMTCT_STAT 35-39, Female 2019 435
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 130
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 235
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 21
PMTCT_STAT 40-49, Female 2019 435
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 130
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 234
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 21
PMTCT_STAT By Age (Numerator): 15-19 2019 171
PMTCT_STAT By Age (Numerator): 20-24 2019 902
PMTCT_STAT By Age (Numerator): 50+ 2019 8
PMTCT_STAT By Number of known positives: 15-19 2019 21
PMTCT_STAT By Number of known positives: 20-24 2019 164
PMTCT_STAT By Number of new negative: 15-19 2019 140
PMTCT_STAT By Number of new negative: 20-24 2019 719
PMTCT_STAT By Number of new negative: 50+ 2019 7
PMTCT_STAT By Number of new positives: 15-19 2019 15
PMTCT_STAT By Number of new positives: 20-24 2019 48
PMTCT_STAT Number of new ANC and L&D clients 2019 2,561
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 2,635
PMTCT_STAT_den 25-29, Female 2019 359
PMTCT_STAT_den 30-34, Female 2019 359
PMTCT_STAT_den 35-39, Female 2019 359
PMTCT_STAT_den 40-49, Female 2019 359
PMTCT_STAT_den By Age (Denominator): <15-19 2019 196
PMTCT_STAT_den By Age (Denominator): 10-14 2019 5
PMTCT_STAT_den By Age (Denominator): 20-24 2019 886
PMTCT_STAT_den By Age (Denominator): 50+ 2019 38
PP_PREV 25-29, Female 2019 18
PP_PREV 25-29, Male 2019 36
PP_PREV 30-34, Female 2019 18
PP_PREV 30-34, Male 2019 36
PP_PREV 35-39, Female 2019 18
PP_PREV 35-39, Male 2019 36
PP_PREV 40-49, Female 2019 18
PP_PREV 40-49, Male 2019 36
PP_PREV Age/sex: 10-14 Female 2019 758
PP_PREV Age/sex: 10-14 Male 2019 4
PP_PREV Age/sex: 15-19 Female 2019 2,303
PP_PREV Age/sex: 15-19 Male 2019 16
PP_PREV Age/sex: 20-24 Female 2019 1,113
PP_PREV Age/sex: 20-24 Male 2019 24
PP_PREV Age/sex: 50+ Female 2019 4
PP_PREV Age/sex: 50+ Male 2019 11
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 4,454
PP_PREV Sum of Age/Sex disaggregates 2019 4,233
PrEP_NEW 25-29, Female 2019 35
PrEP_NEW 25-29, Male 2019 15
PrEP_NEW 30-34, Female 2019 24
PrEP_NEW 30-34, Male 2019 19
PrEP_NEW 35-39, Female 2019 24
PrEP_NEW 35-39, Male 2019 19
PrEP_NEW 40-49, Female 2019 24
PrEP_NEW 40-49, Male 2019 15
PrEP_NEW Female 15-19 2019 58
PrEP_NEW Female 20-24 2019 204
PrEP_NEW Female 50+ 2019 10
PrEP_NEW FSW 2019 68
PrEP_NEW Male 15-19 2019 5
PrEP_NEW Male 20-24 2019 29
PrEP_NEW Male 50+ 2019 10
PrEP_NEW MSM 2019 35
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 488
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 181
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 270
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 451
TB_PREV By Age/Sex (Numerator): <15, Female 2019 3
TB_PREV By Age/Sex (Numerator): <15, Male 2019 2
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 69
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 33
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 108
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 3,028
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 99
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 72
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 1,820
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 1,039
TB_PREV_den IPT, Life-long ART, New, Positive 2019 3,028
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 21
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 217
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 21
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 384
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 643
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 633
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 22
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 218
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 22
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 373
TX_CURR 25-29, Female, Positive 2019 3,691
TX_CURR 25-29, Male, Positive 2019 882
TX_CURR 30-34, Female, Positive 2019 2,809
TX_CURR 30-34, Male, Positive 2019 1,371
TX_CURR 35-39, Female, Positive 2019 2,809
TX_CURR 35-39, Male, Positive 2019 1,365
TX_CURR 40-49, Female, Positive 2019 1,915
TX_CURR 40-49, Male, Positive 2019 1,365
TX_CURR Age/Sex: <1 2019 13
TX_CURR Age/Sex: <1-9 2019 641
TX_CURR Age/Sex: 10-14 Female 2019 689
TX_CURR Age/Sex: 10-14 Male 2019 691
TX_CURR Age/Sex: 15-19 Female 2019 884
TX_CURR Age/Sex: 15-19 Male 2019 809
TX_CURR Age/Sex: 20-24 Female 2019 2,466
TX_CURR Age/Sex: 20-24 Male 2019 1,078
TX_CURR Age/Sex: 50+ Female 2019 1,533
TX_CURR Age/Sex: 50+ Male 2019 493
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 25,504
TX_CURR Sum of age/sex disaggregates 2019 1,693
TX_NEW 25-29, Female, Positive 2019 196
TX_NEW 25-29, Male, Positive 2019 30
TX_NEW 30-34, Female, Positive 2019 226
TX_NEW 30-34, Male, Positive 2019 36
TX_NEW 35-39, Female, Positive 2019 56
TX_NEW 35-39, Male, Positive 2019 36
TX_NEW 40-49, Female, Positive 2019 56
TX_NEW 40-49, Male, Positive 2019 12
TX_NEW Breastfeeding status 2019 17
TX_NEW By Age/Sex: <1 2019 18
TX_NEW By Age/Sex: 1-9 2019 154
TX_NEW By Age/Sex: 10-14 Female 2019 66
TX_NEW By Age/Sex: 10-14 Male 2019 53
TX_NEW By Age/Sex: 15-19 Female 2019 71
TX_NEW By Age/Sex: 15-19 Male 2019 186
TX_NEW By Age/Sex: 20-24 Female 2019 244
TX_NEW By Age/Sex: 20-24 Male 2019 596
TX_NEW By Age/Sex: 50+ Female 2019 28
TX_NEW By Age/Sex: 50+ Male 2019 6
TX_NEW By Key populations: People who inject drugs (PWID) 2019 1
TX_NEW FSW 2019 5
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 2,069
TX_NEW People in prisons and other enclosed settings 2019 29
TX_NEW Pregnancy status 2019 166
TX_NEW Sum of Age/Sex disaggregates 2019 1,250
TX_PVLS <15, Undocumented Test Indication, Female 2019 35
TX_PVLS <15, Undocumented Test Indication, Male 2019 93
TX_PVLS 15+, Undocumented Test Indication, Female 2019 398
TX_PVLS 15+, Undocumented Test Indication, Male 2019 248
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 26,919
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 480
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 215
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 510
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 226
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 12,227
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 3,180
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 7,337
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 1,970
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,426
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 511
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 1,937
TX_RET Numerator by Status: Breastfeeding 2019 9
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 1,967
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,278
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 689
TX_RET_den Denominator by Status: Breastfeeding 2019 11
TX_RET_den Denominator by Status: Pregnant 2019 256
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 22,297
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 938
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 924
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 11,681
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 8,753
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 601
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 109
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 788
Cross Cutting Budget Categories and Known Amounts Total: $1,340,773
Gender: Gender Equality $87,409
Equity in HIV prevention, care, treatment and support
Implementation
Capacity building
Human Resources for Health $94,610
Adolescent Girls and Young Women (AGYW) $1,158,754